

Selected Innovative Medicines in Development as of July 15, 2026



DARZALEX (daratumumab) Frontline multiple myeloma transplant ineligible (CEPHEUS)	INLEXZO (gemcitabine intravesical delivery system) Non Muscle Invasive Bladder Cancer (SunRISe-1)	RYBREVANT (amivantamab) Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)
RYBREVANT (amivantamab) Head and Neck Cancer (ORIGAMI-4)	TALVEY (talquetamab) Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumentAL-3)	TECVAYLI (teclistamab) Multiple Myeloma 1-3PLs (MajesTEC-3)
TECVAYLI (teclistamab) Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)	bleximenib Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine (cAMeLot-2)	bleximenib Acute Myeloid Leukemia (cAMeLot-3)
CARVYKTI (Ciltacabtagene autoleucel) Frontline Multiple Myeloma TNI (CARTITUDE-5)	CARVYKTI (Ciltacabtagene autoleucel) Frontline Multiple Myeloma Transplant Eligible vs ASCT (CARTITUDE-6)	erda-iDRS (erdafitinib intravesical delivery system) Non Muscle Invasive Bladder Cancer (MoonRISe-1)
erda-iDRS (erdafitinib intravesical delivery system) High Risk Non Muscle Invasive Bladder Cancer (MoonRISe-3)	ERLEADA (apalutamide) Localized Prostate Cancer (ATLAS)	ERLEADA (apalutamide) High Risk Prostate Cancer (PROTEUS)
INLEXZO (gemcitabine intravesical delivery system) Non Muscle Invasive Bladder Cancer BCG-naïve High Risk (SunRISe-3)	INLEXZO (gemcitabine intravesical delivery system) High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5)	JNJ-1900 (NBTXR3) Head and Neck Cancer Platinum Ineligible
pasritamig Metastatic Castration-Resistant Prostate Cancer (KLK2-comPAS)	pasritamig Metastatic Castration-Resistant Prostate Cancer (KLK2-PASenger)	ramantamig Relapsed Refractory Multiple Myeloma (TRIllogy-4)
ramantamig Relapsed Refractory Multiple Myeloma (TRIllogy-5)	RYBREVANT (amivantamab) Colorectal Cancer (ORIGAMI-2)	RYBREVANT (amivantamab) Colorectal Cancer 2L (ORIGAMI-3)

RYBREVANT (amivantamab) Head and Neck Cancer (ORIGAMI-5)
TALVEY (talquetamab) TIE NDMM in combination with DR (MajesTEC-7)
bleximenib Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1)
TALVEY + TECVAYLI Relapsed Refractory Multiple Myeloma (RedirectT-1)
JNJ-1900 (NBTXR3) Head and Neck Cancer Platinum Eligible
JNJ-2638 Gastrointestinal Cancer
JNJ-4306 Hematological Malignancies
JNJ-4916 Lung Cancer

TALVEY + TECVAYLI Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)
TECVAYLI (teclistamab) TE NDMM maintenance (MajesTEC-4)
JNJ-0683 (ARX788) Breast Cancer
JNJ-0387 Solid Tumors
JNJ-1981 ER (Cisplatin Extended Release) Solid Tumors
JNJ-2761 Multiple Myeloma
JNJ-4362 (HLD-0117) Breast Cancer
JNJ-6143 (HLD-0915) Prostate Cancer

TALVEY (talquetamab) Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)
TECVAYLI (teclistamab) TIE NDMM in combination with DR (MajesTEC-7)
JNJ-1900 (NBTXR3) Lung Cancer
JNJ-1493 Hematological Malignancies
JNJ-2175 Solid Tumors
JNJ-3413 Lymphoma
JNJ-4680 Lung Cancer
JNJ-6692 Hematological Malignancies

Oncology (3 of 3)

JNJ-7446

Lung Cancer

JNJ-9401

Prostate Cancer

JNJ-8177 (ARX517)

Prostate Cancer

JNJ-9892

Hematological Malignancies

JNJ-8377

Lymphoma

JNJ-9968

Hematological Malignancies

ICOTYDE (icotrokinra) Psoriasis (ICONIC)	nipocalimab Warm Autoimmune Hemolytic Anemia (ENERGY)	STELARA (ustekinumab) Pediatric Crohn's Disease (UNITI JR)
STELARA (ustekinumab) Pediatric Ulcerative Colitis (UNIFI JR)	STELARA (ustekinumab) Pediatric Juvenile Psoriatic Arthritis (PSUMMIT JR)	TREMFYA (guselkumab) Psoriatic Arthritis Structural Damage (APEX)
TREMFYA (guselkumab) Pediatric Juvenile Psoriatic Arthritis	icotrokinra Ulcerative Colitis (ICONIC-UC)	icotrokinra Psoriatic Arthritis (ICONIC-PsA)
JNJ-4804 Co-antibody Therapy Ulcerative Colitis	JNJ-4804 Co-antibody Therapy Crohn's Disease	nipocalimab Systemic Lupus Erythematosus
nipocalimab Sjogren's Disease	nipocalimab Hemolytic Disease of the Fetus and Newborn (AZALEA)	nipocalimab Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA)
TREMFYA (guselkumab) Pediatric Crohn's Disease (MACARONI-23)	TREMFYA (guselkumab) Pediatric Ulcerative Colitis (QUASAR JR)	icotrokinra Crohn's Disease (ICONIC-CD)
JNJ-4804 Co-antibody Therapy Psoriatic Arthritis	JNJ-5223 Psoriatic Arthritis	JNJ-5939 Atopic Dermatitis
JNJ-7528 Atopic Dermatitis	nipocalimab Idiopathic Inflammatory Myopathy	JNJ-5108 Immunological Diseases

JNJ-6848
Immunological Diseases

JNJ-8638
Immunological Diseases

CAPLYTA (lumateperone)
Adjunctive Treatment for Major Depressive Disorder

nipocalimab
Chronic Inflammatory Demyelinating Polyneuropathy (ARISE)

ITI-1284
Generalized Anxiety Disorder

JNJ-2056 (tau active immunotherapy) ¹
Alzheimer's Disease (RETAIN)

CAPLYTA (lumateperone)
Bipolar Mania

seltorexant
Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms (OARS)

ITI-1284
Alzheimer's Disease-Related Psychosis

JNJ-5120
Major Depressive Disorder

CAPLYTA (lumateperone)
Pediatric Psychiatric Indications

SPRAVATO (esketamine)
Major Depressive Disorder with Suicidal Ideation
Pediatrics

ITI-1284
Alzheimer's Disease-Related Agitation

Select Other Areas

UPTRAVI (selexipag)
Pediatric Pulmonary Arterial Hypertension (SALTO)

milvexian (Factor Xla)
Atrial Fibrillation

macitentan
Pulmonary Arterial Hypertension 75mg (UNISUS)

SIRTURO
Leprosy

milvexian (Factor Xla)
Secondary Stroke Prevention

SIRTURO
Tuberculosis Long Acting

¹ AC Immune ACI-35.030.

*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of July 15, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Strategic Partnerships, Collaborations, and Licensing arrangements -milvexian: Bristol Myers Squibb; TREMFYA: MorphoSys AG; JNJ-2113: Protagonist Therapeutics; Tau Immunotherapy: AC Immune SA; SPRAVATO: Icahn School of Medicine at Mount Sinai, National Institutes of Health & Yale University; CAPLYTA: Bristol Myers Squibb; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; DARZALEX and DARZALEX FASPRO: Genmab A/S; ERLEADA: Regents of California and Memorial Sloan Kettering; CARVYKTI: Legend Biotech; AKEEGA: TESARO, an oncology-focused business within GSK; LAZCLUZE: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); CD20-directed autologous CAR-Ts: Cellular Biomedicine Group, Inc. (CBMG); JNJ-5120: Contineum Therapeutics; NBTXR3: Nanobiotix; A2a Receptor Antagonist: AdoRx Therapeutics Limited